ANDA 209019, held by Padagis Israel. Ingenol Mebutate.
As of Nov 16, 2026, ANDA 209019 (Ingenol Mebutate), held by Padagis Israel, was first approved by FDA on Jan 9, 2019, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 9, 2019 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ingenol Mebutate0.05% · gel;topical | Ingenol Mebutate | Discontinued |
| Mar 19, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 5, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 26, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 9, 2019 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters